In addition, there is evidence that the CCR5Δ32 mutation in humans, which results in loss of function of CCR5, is modestly protective against RA [50]–[52] and correlates with prolonged disease-free intervals in MS patients [53], [54]; however, these findings have not been consistent [55]–[58]. This evidence concerns the gene CCR5 and myeloid sarcoma.